Therapeutic monitoring of 120 hours continuous 5-fluorouracil associated with cisplatin.

被引:0
|
作者
Coudert, B [1 ]
DeGislain, C [1 ]
Beltramo, JL [1 ]
Guigues, B [1 ]
Mayer, F [1 ]
Bruchon, Y [1 ]
Riedinger, JM [1 ]
Fargeot, P [1 ]
Dumas, M [1 ]
Guerrin, J [1 ]
机构
[1] CHU, TOXICOL LAB, F-21034 DIJON, FRANCE
关键词
5-fluorouracil; therapeutic monitoring;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For 31 patients treated by continuous 5-fluorouracil with cisplatin, a therapeutic monitoring of 5-fluorouracil is performed, based on the 48 first hours area under the curve (AUC) and the total AUC. The 5-fluorouracile taylorization allows to reduce some toxicity's while preserving art efficiency (objective responses 42%). Many patients are considered with potentially low 5-fluorouracile clearance. Dose reductions of 5-fluorouracile are frequent, reach 50% during the third cure and allow the achievement of targeted AUC. The role of cisplatin in this necessary reduction of dose is unknown.
引用
收藏
页码:847 / 852
页数:6
相关论文
共 50 条
  • [41] Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin
    Ducreux, M
    Rougier, P
    Fandi, A
    Clavero-Fabri, MC
    Villing, AL
    Fassone, F
    Fandi, L
    Zarba, J
    Armand, JP
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (06) : 653 - 656
  • [42] A phase I study of continuous administration of 5-fluorouracil/cisplatin in advanced uterine cervical cancer
    Yoshida, Y
    Goto, K
    Kawahara, K
    Kurokawa, T
    Shukunami, K
    Kotsuji, F
    [J]. ANTICANCER RESEARCH, 2002, 22 (6B) : 3473 - 3476
  • [43] CLINICAL PHARMACOKINETICS OF 3-DAY CONTINUOUS INFUSION CISPLATIN AND DAILY BOLUS 5-FLUOROURACIL
    BELLIVEAU, JF
    POSNER, MR
    CRABTREE, GW
    WEITBERG, AB
    WIEMANN, MC
    CUMMINGS, FJ
    OLEARY, GP
    INGERSOLL, E
    CALABRESI, P
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) : 115 - 117
  • [44] A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
    Ikeda, M
    Okusaka, T
    Ueno, H
    Takezako, Y
    Morizane, C
    [J]. CANCER, 2005, 103 (04) : 756 - 762
  • [45] Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects
    Mindt, Sonani
    Aida, Sihem
    Merx, Kirsten
    Mueller, Annette
    Gutting, Tobias
    Hedtke, Maren
    Neumaier, Michael
    Hofheinz, Ralf-Dieter
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2019, 57 (07) : 1012 - 1016
  • [46] Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin,cisplatin, and 5-fluorouracil regimen for advanced gastric cancer:A systematic review and meta-analysis
    Bo Li
    Lian Chen
    Hong-Liang Luo
    Feng-Ming Yi
    Yi-Ping Wei
    Wen-Xiong Zhang
    [J]. World Journal of Clinical Cases, 2019, (05) : 600 - 615
  • [47] Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
    Li, Bo
    Chen, Lian
    Luo, Hong-Liang
    Yi, Feng-Ming
    Wei, Yi-Ping
    Zhang, Wen-Xiong
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (05) : 600 - 615
  • [48] CISPLATIN PLUS CONTINUOUS INFUSION OF 5-FLUOROURACIL FOR 5 DAYS EFFECTIVE FOR PATIENTS WITH ADVANCED GASTRIC-CANCER
    OKADA, Y
    ANAI, H
    HATTORI, T
    MAEHARA, Y
    NISHIMURA, J
    SUGIMACHI, K
    NAWATA, H
    [J]. ANTI-CANCER DRUGS, 1991, 2 (05) : 453 - 456
  • [49] Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy
    Beumer, Jan H.
    Chu, Edward
    Allegra, Carmen
    Tanigawara, Yusuke
    Milano, Gerard
    Diasio, Robert
    Kim, Tae Won
    Mathijssen, Ron H.
    Zhang, Li
    Arnold, Dirk
    Muneoka, Katsuki
    Boku, Narikazu
    Joerger, Markus
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (03) : 598 - 613
  • [50] PREVENTION OF 5-FLUOROURACIL ASSOCIATED CARDIOTOXICITY
    DAVIDSON, JA
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1994, 24 (03): : 321 - 321